Larimar Therapeutics (LRMR) Invested Capital (2016 - 2020)
Historic Invested Capital for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $102.6 million.
- Larimar Therapeutics' Invested Capital rose 7141.12% to $102.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $102.6 million, marking a year-over-year increase of 7141.12%. This contributed to the annual value of -$694000.0 for FY2019, which is 10074.41% down from last year.
- Larimar Therapeutics' Invested Capital amounted to $102.6 million in Q3 2020, which was up 7141.12% from $112.5 million recorded in Q2 2020.
- In the past 5 years, Larimar Therapeutics' Invested Capital ranged from a high of $154.4 million in Q1 2016 and a low of -$694000.0 during Q4 2019
- Its 5-year average for Invested Capital is $90.5 million, with a median of $93.3 million in 2018.
- In the last 5 years, Larimar Therapeutics' Invested Capital crashed by 10074.41% in 2019 and then skyrocketed by 7141.12% in 2020.
- Over the past 5 years, Larimar Therapeutics' Invested Capital (Quarter) stood at $121.7 million in 2016, then crashed by 35.74% to $78.2 million in 2017, then rose by 19.25% to $93.3 million in 2018, then plummeted by 100.74% to -$694000.0 in 2019, then soared by 14889.77% to $102.6 million in 2020.
- Its Invested Capital stands at $102.6 million for Q3 2020, versus $112.5 million for Q2 2020 and $50.7 million for Q1 2020.